![Yale @ AWV-7785[57].jpg](https://images.squarespace-cdn.com/content/v1/66f1a668cb2280496659b3a0/f6e751ae-7da8-4189-8a99-08fc362f006f/Yale+%40+AWV-7785%5B57%5D.jpg)
Consortium Member of the Month
Our consortium member of the month for the month of April goes to Sana Ali from Memorial Sloan Kettering!
Sana Ali
Clinical Research Coordinator
We are delighted to recognize Sana Ali as our MPN‑RC Consortium Member of the Month for April. Sana has made outstanding contributions to the MPN‑RC 106 Tissue Bank, playing a key role in consenting patients and collecting samples at Memorial Sloan Kettering. She consistently ensures that all patient information, including sample collection timepoints, is accurately and thoroughly recorded in our REDCap database. Her diligence, reliability, and commitment greatly strengthen the quality and integrity of our research efforts. We are truly grateful for everything Sana brings to the MPN‑RC.
Nominated by: Victoria Rivera
Sana, thank you so much for all of the phenomenal work you have done for the consortium.
Keep up the great work!
MPN-RC Monthly Publication
Title: Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images
Author(s): Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, James M. Dolezal, Andrew T. Kuykendall, Raffaella Santi, Ling Zhang, Avani M. Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Mohamed E. Salama, Alexander T. Pearson & Ronald Hoffman
We are HIRING!
Mount Sinai Health System is looking to hire Senior Associate Researchers and Scientists. Use the links below for more information and to apply for the position(s).
ASH Conference 2025
-
![]()
(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
-
![]()
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
-
![]()
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!
-
![]()
(Left to Right: Md. Babu Mia, Noushin Rahnamay, Dr. Bridget Marcellino, and Dr. Raajit Rampal) The Mount Sinai and Memorial Sloan Kettering group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
ASH Abstracts
-
Marina Kremyanskaya, MD,PhD
Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial
-
John Crispino, PhD,MBA
Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms
-
John Mascarenhas, MD
Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A
-
Andrew Kuykendall, MD
A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1
-
Min Lu, MD,PhD
Myelofibrosis stem cell fitness requires microenvironmental cell interactions
-
Xiaoli Wang, MD,PhD
Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells
-
MD Babu Mia, PhD
Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis
